Lista de obras - Davide Melisi - Dominio Público Uruguay

A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma.

artículo científico publicado en 2017

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial

artículo científico publicado en 2020

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

artículo científico publicado en 2020

Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.

artículo científico publicado en 2017

Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data

artículo científico publicado en 2018

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

artículo científico publicado en 2016

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.

artículo científico publicado en 2018

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

artículo científico publicado en 2011

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

artículo científico publicado en 2004

CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy

scientific article published on 01 August 2018

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib

artículo científico publicado en 2020

Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment

artículo científico publicado en 2015

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

artículo científico publicado en 2005

Current Strategies to Overcome Resistance to ALK-Inhibitor Agents

artículo científico

Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis.

artículo científico publicado en 2017

EMT and Treatment Resistance in Pancreatic Cancer.

artículo científico publicado en 2017

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

artículo científico publicado en 2016

HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies

artículo científico publicado en 2020

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

artículo científico publicado en 2017

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

artículo científico publicado en 2015

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes

artículo científico publicado en 2018

Key cancer cell signal transduction pathways as therapeutic targets.

artículo científico publicado en 2006

MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.

artículo científico publicado en 2018

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.

artículo científico

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

artículo científico publicado en 2015

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

scientific article published on 27 September 2019

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1

artículo científico publicado en 2011

NF-κB as a target for pancreatic cancer therapy.

artículo científico

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

artículo científico publicado en 2019

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity

artículo científico publicado en 2009

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

artículo científico publicado en 2018

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

artículo científico

Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

scientific article published on 24 July 2019

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance

artículo científico publicado en 2018

Pancreatic cancer: between bench and bedside

scientific article published on 01 June 2012

Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells.

artículo científico publicado en 2014

Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

scientific article published on 09 October 2020

Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension

artículo científico

Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer

artículo científico publicado en 2020

Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

artículo científico publicado en 2019

Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma

scientific article published on 05 September 2019

Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.

artículo científico publicado en 2018

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

artículo científico publicado en 2016

Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.

artículo científico publicado en 2018

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin

scientific article published on 17 November 2018

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

artículo científico publicado en 2017

Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results

artículo científico publicado en 2018

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

artículo científico

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study

scientific article published on 11 December 2018

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

artículo científico publicado en 2017

TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.

artículo científico publicado en 2017

TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

artículo científico publicado en 2015

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

artículo científico publicado en 2019

Targeting the epidermal growth factor receptor in solid tumors: focus on safety.

artículo científico publicado en 2014

The curious case of Gαs gain-of-function in neoplasia.

artículo científico publicado en 2018

The development of PARP as a successful target for cancer therapy

artículo científico publicado en 2017

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

artículo científico publicado en 2004

Toll-Like Receptor 9 Agonists for Cancer Therapy

artículo científico publicado en 2014

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

artículo científico publicado en 2011

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

artículo científico publicado en 2008

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

artículo científico publicado en 2005

Lista de obras de Davide Melisi

A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma.

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.

Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib

Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

Current Strategies to Overcome Resistance to ALK-Inhibitor Agents

Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis.

EMT and Treatment Resistance in Pancreatic Cancer.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes

Key cancer cell signal transduction pathways as therapeutic targets.

MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1

NF-κB as a target for pancreatic cancer therapy.

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance

Pancreatic cancer: between bench and bedside

Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells.

Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension

Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer

Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma

Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.

TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Targeting the epidermal growth factor receptor in solid tumors: focus on safety.

The curious case of Gαs gain-of-function in neoplasia.

The development of PARP as a successful target for cancer therapy

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

Toll-Like Receptor 9 Agonists for Cancer Therapy

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.